Highly Galactosylated Anti-HER2 Antibody (m860), a Biobetter Antibody Antibody (CAT#: BioBet-GA-489ZP) Datasheet

Target
HER2
Isotype
Whole Humanized Antibody
Indication
HER2-positive breast cancer; metastatic breast cancer
Classification
Therapeutic antibody; biobetter
Patent
The patents on Herceptin will expire in the US in June 2019 and expired in Europe in July 2014.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Trastuzumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ERBB2
Full Name
erb-b2 receptor tyrosine kinase 2
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Alternative Names
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Gene ID
UniProt ID
Antibody Clone
m860
Host
Mouse
Species Reactivity
Human
Description
M860 binds to cell surface-associated Her2 with an affinity comparable to that of trastuzumab (Herceptin庐), but binds to a different epitope.

Similar to the parental antibody Trastuzumab, glycoengineered ADCC-enhancement Trastuzumab works by targeting HER2 / neu receptors on cancer cells. In the normal body, the HER2 protein receptor is displayed on the cell surface and sends signals by inducing cell division and reproduction, thus indicating normal cell growth. In some cancerous breast tissues, HER2 is excessive (HER2 / neu overexpressed), triggering excessive cell division and reproduction. Trastuzumab attaches to the HER2 receptor to inhibit cell proliferation, prevent further cancer growth and slow cancer progression. It can also work by stimulating immune mechanisms - antibody-dependent cellular cytotoxicity (ADCC).

It is suitable for treating early HER2-positive early breast cancer or metastatic breast cancer that substantially overexpresses HER2. Approved for gastric cancer, metastatic gastroesophageal junction adenocarcinoma, and metastatic adenocarcinoma of the gastro-esophageal junction, provided that these cancers overexpress HER2.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK